Adding nitroglycerin + hydralazine to CHF regimens is beneficial

Nitroglycerin + hydralazine in CHF patients is beneficial in african americans, but it’s effect in other racial and ethnic groups is less clear. In the retrospective cohort of CHF patients admitted with acute decompensated CHF (with cardiac index <2.2), researchers compared outcomes in those discharged on ACE/ARB, versus those discharged on ACE/ARB combined with isosorbide dinitrate + hydralazine (I/H group). Those in the I/H group had lower all cause mortality (34% versus 41%), and lower mortality/CHF readmissions (70% versus 85%). The benefit was found irrespective of race. I/H addition to ARB/ACE in CHF is associated with lower mortality (abstract).

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment